Information Center

  • Move News
  • Move FAQ
  • Move Queries&Feedback

News News

Total 27

News Search
  • Samyang Biopharm 2018.01.29
    Samyang Biopharmaceuticals Corp. Attends, ‘Arab Health 2018’
    Samyang Biopharmaceuticals Corp.  Attends, ‘Arab Health 2018’

    Samyang Biopharmaceuticals Corporation attended ‘Arab Health 2018’, the 43rd international healthcare exhibition held in Dubai from January 29 to February 1, 2018.   At this exhibition Samyang Biopharmaceuticals Corporation showcased its wound care products, highlighting the superiority of the suture products such as Trisorb, Neosorb, Monosorb, Monofast, and Antibacterial sutures, as well as ORC styptic products such as Surgi-Guard.   Samyang Biopharmaceuticals Corporation networked with over 30 overseas clients at the ‘Arab Health 2018’ and shared their thoughts on business for the year 2018.

  • Samyang Biopharm 2018.01.16
    Samyang Biopharmaceuticals Corp. Signs Technology Transfer Agreement with KIST for Anticancer Immunotherapy Drug
    Samyang Biopharmaceuticals Corp. Signs Technology Transfer Agreement with KIST for Anticancer Immunotherapy Drug

      Samyang Biopharmaceuticals Corp. is accelerating the development of new biological anticancer drugs through open innovation.   Samyang Biopharmaceuticals Corp. revealed that they held a signing ceremony with the Korea Institute of Science and Technology (KIST) for the technology transfer of the new Nanocage on the 16th at the main branch of KIST in Seoul. The new technology introduced by Samyang Biopharmaceuticals Corp. is an anticancer immunotherapy drug delivery system that binds immune checkpoint inhibitors to the surface of a Nanocage containing an anticancer drug.   The immune checkpoint inhibitors bound to the surface of the Nanocage strengthens the body’s immune system and activates the attack of immunocytes on cancer cells. The anticancer drug embedded in the interior of the Nanocage directly attacks and kills cancer cells. Samyang Biopharmaceuticals Corp. plans to develop a new anticancer immunotherapy drug utilizing this technology.   Anticancer immunotherapy drugs are classified as 3rd generation anticancer drugs. They are drugs that treat cancer by causing immunocytes within the body to attack cancer cells. Anticancer immunotherapy drugs block the channel by which cancer cells attack immunocytes(immune checkpoint inhibitors), or strengthen the immunocytes to help them attack the cancer cells.   The global anticancer immunotherapy drug market is expected to increase by about 20 times from $1.4 billion in 2014 to $27.6 billion in 2020.   In the future, Samyang Biopharmaceuticals Corp. plans to develop a new anticancer immunotherapy drug by conducting clinical tests in which Samyang Biopharmaceuticals Corp.’s anticancer drug is embedded on the Nanocage before being administered or clinical tests for the Nanocage alone, after conducting a proof of concept with KIST.   Representative EOM Tae-Ung of Samyang Biopharmaceuticals Corp. explained said, “Samyang Biopharmaceuticals Corp. is pursuing open innovation through active cooperation with other institutes. With the introduction of KIST’s new Nanocage technology, Samyang Biopharmaceuticals Corp. will accelerate the development of new biopharmaceuticals.” Samyang Biopharmaceuticals Corp. is a specialized affiliate of Samyang Group’s biopharmaceutical business, with about 200 head office and research staff currently working at Samyang Discovery Center in Pangyo.   Samyang Biopharmaceuticals Corp. has secured growth momentum by trailblazing the global market with its distinctive technology in the medicine and medical device (MD) field, and is focusing its research and development in three key areas: ▲improved drug products using drug delivery systems (DDS) ▲new biopharmaceuticals to lead the future anticancer treatment and ▲medical devices (MD) using cutting-edge biodegradable materials.  

  • Samyang Biopharm 2018.01.03
    Samyang Biopharmaceuticals Corp. Wins ‘Palseron Inj.’ Patent Suit
    Samyang Biopharmaceuticals Corp. Wins ‘Palseron Inj.’ Patent Suit

      Samyang Biopharmaceuticals Corporation has won a first a patent suit on Palseron (Ingredient: Palonosetron Hydrochloride) against a Switzerland-based pharmaceutical company, Helsinn Healthcare SA.   On December 21, 2017, the 63rd Civil Affairs Division of the Seoul Central District Court ruled that all of the plaintiff’s claims in relation to patent infringement prohibition and prevention for ‘Alroxi’ (Ingredient: Palonosetron Hydrochloride) filed by Helsinn Healthcare and CJ Healthcare in November 2016, would be dismissed.   Alroxi, developed by Helsinn Healthcare, is a drug that inhibits nausea and vomiting that occurs in patients undergoing chemotherapy. CJ Healthcare signed an exclusive distribution agreement with Helsinn Healthcare and has been selling Alroxi in Korea since 2007. Its domestic market size is valued at about KRW 25 billion.   Samyang Biopharmaceuticals Corp. avoided patent infringement by developing a technology that secures the stability of the drug without using antioxidants (EDTA), a composition of Alroxi. In May of last year Samyang Biopharmaceuticals Corp. utilized this technology to launch ‘Palseron Inj.’ in Korea. When a generic drug product is released, the prices of both the originator and generic medication fall, reducing the financial burden on patients and cutting the overall health insurance budget.   A Samyang Biopharmaceuticals Corp. representative explained, “Breaking away from the fixed idea that antioxidants must be used to ensure stability, we identified the root cause that compromises the drug’s stability and developed a product that secures stability without antioxidants (EDTA), which is included in the existing patent.”   Meanwhile, an associate at Boryung Pharmaceutical responsible for sales of Palseron Inj. added, “Samyang Biopharmaceuticals Corp.’s excellent quality and Boryung Pharmaceutical’s, business channels and marketing experience in the oncology market will produce a great synergy.”

  • Samyang Biopharm 2017.12.08
    Samyang Biopharm Participated in ‘MEDICA 2017’
    Samyang Biopharm Participated in ‘MEDICA 2017’

      Samyang Biopharm participated in the 49th international medical trade fair, ‘MEDICA 2017’ held in Dusseldorf, Germany, from November 13 to 16, 2017.  At this fair, Samyang Biopharm conducted a promotional campaign for its new products such as ‘Trisorb’ and ‘Monosorb Undied’ and enjoyed cooperation with more than 40 companies overseas. Also, members of the MD plant and Biopharmaceuticals Research Center of Samyang Biopharm participated in the event to explore new products in the medical device business as well as the latest updates in the industry. Meanwhile, ‘MEDICA 2017’, the largest International Forum for Medicine in the world, was first held in 1970 and is being held in the city of Düsseldorf, Germany every November since then. This year the exhibition attracted 5,100 companies from 70 countries worldwide.  

  • Samyang Biopharm 2017.10.24
    Samyang Biopharm Participates in ‘CPhI Worldwide 2017’
    Samyang Biopharm Participates in ‘CPhI Worldwide 2017’

    ▲ Samyang Biopharm participated in the international pharmaceutical exhibition ‘CPhI Worldwide 2017’ from October 24 to 26.   From October 24 to 26, Samyang Biopharm participated in the international pharmaceutical exhibition ‘CPhI Worldwide 2017’ held in Frankfurt, Germany.   CPhI Worldwide is the world’s largest pharmaceutical exhibition with over 40,000 participants from as many as 150 countries around the world. It is held annually in major cities of Europe.   Samyang Biopharm received the opportunity to expand exports by promoting our company’s products and technology including anti-cancer drugs, patches and DDS (Drug Delivery System), and through meetings with overseas pharmaceutical companies.

  • Samyang Biopharm 2017.08.21
    Samyang Biopharmaceuticals Corp. acquires approval for ‘Lenalid Tab’, the First Lenalidomide in Tablet Form.
    Samyang Biopharmaceuticals Corp. 
acquires approval for ‘Lenalid Tab’, 
the First Lenalidomide in Tablet Form.

      - Approval for 7 doses of multiple myeloma ‘Lenalid Tab(Ingredient: Lenalidomide)’ - The first tablet formulation is about 1/3 the size of the original capsule and expects to eliminate disadvantages of capsules by improving patient compliance. - 7 different doses, diversified treatment options are expected to launch after the patent expiration (October 27)   Samyang Biopharmaceuticals Corporation has developed, for the first time, the tablet (pill) form of Lenalidomide, a therapeutic agent for multiple myeloma, and acquired market approval.   Samyang revealed on 17th that the approval consists of a total of 7 doses: 25, 20, 15, 10, 7.5, 5, and 2.5mg of ‘Lenalid® Tab’ (Ingredient: Lenalidomide) for multiple myeloma from the Ministry of Food and Drug Safety on August 14th.   Samyang Biopharmaceuticals Corp. ‘s Lenalid Tab is a generic formulation of Celgene’s ‘Revlimid Capsule’. Compared to the size of the original capsule, the size of Samyang’s newly developed tablet is reduced to nearly 1/3rd (25mg) of the originator, making it more convenient for patient compliance.. The frequent complaints by elderly patients with regard to the capsule which were medicine getting stuck in the mouth, throat, or esophagus have been prevented with the tablet forms.   The additional doses are also great news as Samyang plans to release 20, 7.5, and 2.5mg doses in addition to the existing 4 doses (25, 15, 10 and 5mg) in order to diversify treatment options for patients. An associate of Samyang Biopharmaceuticals Corp. explained, “We are in the process of insurance price negotiation and expect to launch the product after the patent expiration (October 27th).   The administration of the drug is expected to be a lot easier thanks to the new formulation developed by Samyang, and patients will be able to benefit from a greater range of doses to take the medication from according to their needs.” Meanwhile, Samyang Biopharmaceuticals Corp. launched ‘Protezomib® Inj’ 2.5mg injection, a generic formulation for the ‘Velcade (Ingredient: Bortezomib Trimer), which is the first-line treatment of multiple myeloma on August 1st.   The price of Protezomib Inj. 2.5mg has been set at the lowest among other domestically launched drugs, and Samyang’s Protezomib Injection is expected to contribute in reducing the financial burden on patients. Samyang Group has designated its biopharmaceutical business as its future growth engine and is focusing on maximizing Samyang Biopharmaceuticals Corp. ‘s potential to the fullest.   Samyang Group founded the Biopharmaceuticals Research Center in 1992 and established Samyang Biopharmaceuticals Corporation in 2011.   Samyang Biopharmaceuticals Corp. is promoting global market entry with R&D in Medical Device’s absorbable materials and Oncology products with its proprietary Drug Delivery Systems.

  • Samyang Biopharm 2017.07.27
    Samyang Biopharmaceuticals Corp. to take charge in marketing of Transdermals
    Samyang Biopharmaceuticals Corp. 
to take charge in marketing of Transdermals

      Samyang Biopharmaceuticals Corporation has completed product improvement and package renewal for the Nicostop Patch and has now brought its sales function inside, previously outsourced to 3rd parties.   The newly improved Nicostop is bioequivalent to the previous patches with about 26% less nicotine as proven by bioequivalence test. In addition, the product size, as well as a product design, has been modified to improve adhesion and ease-of-use.   Samyang Biopharmaceuticals Corp. and Baekje Pharmaceutical plan to collaborate to bring synergy together with Samyang in charge of marketing Nicostop and Baekje Pharmaceutical responsible for distribution to pharmacies.

  • Samyang Biopharm 2017.07.07
    Samyang Biopharm Held Samyang Discovery Center Opening Symposium
    Samyang Biopharm Held Samyang Discovery Center Opening Symposium

    ▲ Samyang Biopharm held Samyang Discovery Center Opening Symposium on July 7.   ▲ Chairman Kim Yoon looking around the medicine exhibition booth at the symposium   ▲ Samyang Biopharm CEO Eom Tae-ung delivering a welcoming speech   ▲ CSO (Chief Strategy Officer) Hyunjung Helen Lee introducing R&D of Samyang Biopharm   ▲ Professor John Bell (University of Ottawa) giving a lecture at Samyang Discovery Center Opening Symposium   On July 7, Samyang Biopharm (CEO: Eom Tae-ung) held a symposium entitled “New Trends of Chemotherapy” in Samyang Discovery Center Auditorium. The symposium was held to commemorate the completion of Samyang Discovery Center. In this symposium, Samyang Biopharm shared the latest trends of research on anticancer drugs with noted Korean and foreign experts and encouraged exchange between participants. As many as 200 people including Korean and foreign researchers, entrepreneurs, and heads of associations relating to chemotherapy participated in the event composed of the official event and the symposium. In the official event, Korea Pharmaceutical and Bio-Pharma Manufacturers Association Chairman Won Hee-mok and Chair-Professor Kim Sung-wan (University of Utah) celebrated the opening of the symposium delivered a congratulatory speech. In addition, Professor Kim Yong-man from Asan Medical Center announced the clinical results of Genexol® PM of Samyang Biopharm. During the symposium, attendees published the results of recent research on immune checkpoint inhibitors, which are the most noteworthy anticancer drug these days, and development of anticancer drugs using viruses. In addition, Professor Bang Yung-jue (Seoul National University), Professor John Bell (University of Ottawa), Professor Omid C. Farokhzad (Harvard University), and Professor Dennis Discher (University of Pennsylvania) attracted attention of visitors by giving a presentation under the theme of “Immune Checkpoint Inhibitors in Gastrointestinal Cancers”, “Oncolytic Virus Combination Therapy Approaches”, “Nanoparticles for Cancer Therapy and Immune Tolerance : From Bench to the Clinic”, and “Interactions of Drug Delivery System with Macrophages as a Foundation for Engineered Macrophage Anti-Cancer Therapy”, respectively. In the welcoming speech, Samyang Biopharm CEO Eom Tae-ung said, “Samyang Biopharm will realize C&D through communication with outside experts. We will make efforts so that Samyang Biopharm can become an R&D hub leading the chemotherapy trends in the future.”

  • Samyang Biopharm 2017.06.09
    Samyang Biopharm Invited Foreign Cancer Specialists and Held a Seminar
    Samyang Biopharm Invited Foreign Cancer Specialists and Held a Seminar

      Samyang Biopharm invited as many as 60 noted cancer specialists from Southeast Asia and held a seminar for six days from June 19 to 25. This seminar is held annually by PT Kalbe Farma Tbk from Indonesia, Mermisi from Georgia, and Samyang Biopharm in order to develop their competencies in anticancer drugs. During the seminar, anticancer specialists looked around anticancer drug manufacturing facilities of Samyang Biopharm Pharmaceuticals Plant, attended the 24th Asia Pacific Cancer Conference held in COEX, and shared their clinical experience and opinions.

  • Samyang Biopharm 2017.01.30
    Samyang BioParm participates in Arab Health 2017
    Samyang BioParm participates in Arab Health 2017

    ▲ Samyang Biopharm participated in Arab Health 2017, a medical device exhibition held in Dubai, United Arab Emirates.   Samyang Biopharm participated in Arab Health 2017, the international medical device exhibition held in Dubai, United Arab Emirates from January 30 to February 2. At this exhibition, Samyang Biopharm introduced the excellence of wound management products such as Trisorb, Neosorb, Monosorb, and Monofast, which are existing suture products, and the recently launched product Surgi-Guard. It also discussed this year's business in meetings with over 30 overseas customers.   Meanwhile, Arab Health, which has been held every January since 1975, is the largest medical industry exhibition in the Middle East. More than 4,400 companies from 70 countries and 136,000 people participated in this year's exhibition.

First Page 1 2 3 Next Page Last Page
1 2 3
News Search